Preclinical PET/SPECT/CT Systems Market Size, Share, and Growth Forecast 2026 - 2033

The global preclinical PET/SPECT/CT systems market size is likely to be valued at US$642.8 million in 2026 and is estimated to reach US$1,130.5 million by 2033, growing at a CAGR of 8.4% during the forecast period from 2026 to 2033, driven by the expanding radioligand therapy pipeline, rising demand for quantitative molecular imaging in drug discovery, and growing adoption of compact multimodality scanners.

Driver: Expanding Radioligand Pipelines to Push Demand for Nuclear Imaging Systems

The commercial success of radioligand therapy is pulling more drug developers into radiopharmaceutical research, and each new candidate needs animal-model data before it reaches clinical testing. Lutathera and Pluvicto generated combined sales of about US$2.8 billion for Novartis in 2025, with Pluvicto alone at roughly US$2.0 billion. Bristol Myers Squibb, AstraZeneca, and Eli Lilly have since built positions through their purchases of RayzeBio, Fusion Pharmaceuticals, and POINT Biopharma, respectively.

Preclinical PET and SPECT are the standard tools for measuring biodistribution, tumor uptake, clearance, and dosimetry of radiolabeled compounds in mice and rats. Perceptive Discovery states that its α-Sight offering supports biodistribution studies, tumor targeting validation, and PK/PD assessment. A rising number of programs, hence translates into more scanners and more demand for isotope-flexible platforms.

Multimodal Imaging to Improve Data Yield per Animal

Research teams increasingly want anatomical, metabolic, and receptor-level information from the same animal in a single session. Combining PET or SPECT with CT gives the functional signal a precise anatomical location and provides the attenuation correction needed for quantitative uptake values. Mordor Intelligence estimates that hybrid systems, including PET/SPECT/CT, will grow at about 9.43% annually through 2031, as investigators seek multi-parametric insights without repeated anesthetic events.

Longitudinal imaging also supports the ethical goal of reducing animal numbers, since the same subject can be tracked over weeks instead of being sacrificed at each time point. Bruker frames its preclinical portfolio around obtaining more endpoints from every animal. This favors scanners with fast acquisition, stable quantification, and integrated analysis software.

Restraint- High Capital Cost and Constrained Research Funding May Slow Instrument Purchases

Preclinical PET/SPECT/CT platforms are expensive to buy and to operate, and a large share of demand comes from academic laboratories that depend on public grants. In the U.S., the Association of American Medical Colleges reported that NIH had obligated US$5.8 billion by March 20, 2026, which was 34% below the amount obligated at the same point in fiscal 2024. Executives at Agilent and other life science tool companies have also said that laboratories are prioritizing core operations over new capital investment. Purchase decisions for high-value imaging systems are hence being delayed or shifted toward shared core facilities.

Operating requirements add further friction. A nuclear imaging suite needs shielded rooms, radioisotope handling authorization, radiochemistry support, and a dependable tracer supply. When ACTREC in India established its facility, it first had to obtain regulatory approval for the layout and authorization to procure radioisotopes. The FDA's April 2025 roadmap to reduce animal testing targets preclinical safety studies rather than imaging, but it signals a longer-term shift of research budgets toward human-relevant methods.

Opportunity- Alpha-emitter Imaging to Create a New Equipment Niche

Targeted alpha therapy is the most significant technical opportunity in this market because conventional scanners were not designed to image alpha emitters. MH3D describes its Alpha-SPECT Mini as a CZT-based platform built to address the inability to image alpha-emitting isotopes directly without relying on surrogate signals. The system supports multi-energy imaging and absolute quantification across complex decay chains.

Demand for this capability is rising with the pipeline. AstraZeneca, Bristol Myers Squibb, and Lilly each acquired actinium-225 developers between October 2023 and March 2024, and Novartis signed a long-term actinium-225 supply agreement with Niowave in February 2026. In April 2026, Perceptive Discovery became the exclusive service provider for MH3D's platform. MILabs, for instance, states that its VECTor system supports quantitative sub-millimeter imaging of high-energy isotopes such as iodine-131 and bismuth-213.

Benchtop Systems and Imaging-as-a-Service to Broaden the Buyer Base

Compact modular scanners are lowering the space and budget barrier that once limited nuclear imaging to large institutions. Bruker's CUBES series offers benchtop PET, SPECT, and CT modules, added through its acquisition of Molecubes, while MILabs has introduced a mini family of benchtop SPECT and PET systems for laboratories with limited space or budgets. Modular designs that share a common animal holder also allow different animals to be imaged on separate modules at the same time.

Outsourcing is opening a parallel route. Contract research organizations such as Perceptive Discovery and Minerva Imaging combine scanners, radiochemistry, and image analysis, giving biotech firms without in-house facilities access to advanced imaging. Each CRO installation also represents a new equipment buyer, particularly for specialized systems that a single small biotech could not justify purchasing.

Product Type Insights

PET/CT systems are predicted to lead with a share of about 40.8% in 2026, as PET offers quantitative, whole-body, dynamic tracer imaging that translates readily to the clinic, while the integrated CT supplies anatomical reference and attenuation correction. A published review of small-animal PET lists translatability, quantitative capability, and dynamic tracing of biochemical processes among its main strengths. Systems such as Mediso's nanoScan and Bruker's Si78 are built for high-throughput work. The same review notes that integrated dual-modality systems are now more common than tri-modality designs.

Trimodal PET/SPECT/CT systems are estimated to be the fastest-growing segment over the forecast period, as radiopharmaceutical development uses both PET and SPECT isotopes, and one platform avoids buying and housing two scanners. Mediso's nanoScan triple modality system combines PET/CT and SPECT/CT in a single device with SPECT resolution down to 0.3 mm in vivo, while the MILabs VECTor images PET and SPECT tracers simultaneously. This is useful for theranostic studies, where a diagnostic tracer and a therapeutic radioligand are followed in the same animal. Higher purchase cost and operating complexity keep the segment smaller than PET/CT for now.

Application Insights

Oncology is anticipated to dominate with a share of around 46.3% in 2026, as tumor models remain the main workload for preclinical nuclear imaging, from FDG-based metabolic studies to receptor-targeted tracers and radioligand therapies. Xenograft imaging with technetium-99m and fluorine-18 compounds is a routine activity at cancer research centers such as ACTREC in India. Radioligand therapy has also raised the stakes. Pluvicto targets PSMA, and Lutathera targets somatostatin receptors, so growing pipelines around these targets require repeated biodistribution and dosimetry studies in tumor-bearing animals.

Neurology is expected to remain in the second position in 2026, as PET imaging of neuroreceptors, glucose metabolism, and protein aggregates helps evaluate central nervous system drug candidates in transgenic and disease models. Bruker lists functional and anatomical neuroimaging among its target application fields, and PET/MR combinations extend this work further. CNS programs also depend on brain penetration and target engagement data, which imaging can measure noninvasively in living animals.

North America Preclinical PET/SPECT/CT Systems Market Trends

North America is expected to dominate the market, accounting for approximately 42.6% of the global share in 2026, driven by its strong pharmaceutical and biotechnology R&D base, well-funded academic imaging facilities, and expanding radiopharmaceutical sector. Service providers such as Perceptive Discovery in Needham, Massachusetts, and instrument developers such as MH3D in Ann Arbor, Michigan, are enhancing capabilities for radioligand research. However, regional demand remains sensitive to federal research funding cycles.

U.S. Preclinical PET/SPECT/CT Systems Market Trends

A share of nearly 69.4% is expected to be held by the U.S. in 2026 in North America, as it has the largest concentration of radiopharmaceutical developers, contract research organizations, and NIH-funded laboratories. The NIH has a fiscal 2026 budget of US$47.2 billion, about 80% of which is awarded through grants and contracts to research institutions. Isotope supply is also scaling domestically. Niowave has started construction on a US$75 million facility in Michigan, while TerraPower has committed US$450 million to a cGMP radioisotope plant. These investments support the preclinical pipelines that need imaging capacity.

Asia Pacific Preclinical PET/SPECT/CT Systems Market Trends

Asia Pacific is expected to be the fastest-growing region, driven by government and university investments in nuclear medicine infrastructure, increasing domestic scanner manufacturing, and declining equipment costs. The introduction of regulatory approvals for radioligand therapies is further supporting regional market development. Pluvicto became the first PSMA-targeted radioligand therapy approved in China in late 2025, potentially encouraging local developers to expand their preclinical radiopharmaceutical research.

China Preclinical PET/SPECT/CT Systems Market Trends

China will likely lead in Asia Pacific in 2026 with a share of about 38.2%, supported by large research spending, a growing biotechnology sector, and domestic scanner manufacturers. Suzhou-based Raycan Technology produces the Trans-PET/CT X5, which has been compared with the Siemens Inveon and Molecubes β-cube systems in a published NEMA image-quality study. Local supply gives research institutes an alternative to imported systems and typically simplifies service support.

India Preclinical PET/SPECT/CT Systems Market Trends

In 2026, India is projected to account for a share of just about 13.8% in Asia Pacific, as preclinical nuclear imaging is concentrated in a small number of government-backed research centers. ACTREC at Tata Memorial Centre, Navi Mumbai, runs a small animal PET/CT facility inaugurated by the chairman of the Atomic Energy Commission and uses it to evaluate technetium-99m and fluorine-18 compounds in mouse xenograft models. The Board of Radiation and Isotope Technology supplies molybdenum-99/technetium-99m generators to nuclear medicine centers across the country, supporting SPECT-based research. Growth will depend on wider access to PET tracers and on funding for imported scanners.

Europe Preclinical PET/SPECT/CT Systems Market Trends

Europe will witness steady growth over the forecast period with a share of roughly 26.4% in 2026 globally, because the region is home to several scanner developers, including MILabs in the Netherlands, Mediso in Hungary, and Molecubes in Belgium, alongside shared research infrastructure. The Euro-BioImaging network also gives researchers shared access to advanced imaging systems. Minerva Imaging in Denmark has also acquired an Alpha-SPECT Mini system, which it describes as the first installed in Europe.

Germany Preclinical PET/SPECT/CT Systems Market Trends

Germany is predicted to register a substantial regional share of approximately 25.3% in 2026, as it combines a strong pharmaceutical base with an active radiopharmaceutical sector. Munich-based ITM is among the companies advancing lutetium-177 candidates, while Berlin-based Eckert & Ziegler is listed among suppliers of actinium-225. Bayer is also among the drugmakers linked to actinium-225 supply deals. These activities create steady demand for preclinical biodistribution and dosimetry work.

U.K. Preclinical PET/SPECT/CT Systems Market Trends

A regional share of nearly 19.6% is predicted to be held by the U.K. in 2026, as cancer research institutions operate shared imaging cores with a wide range of nuclear platforms. The Barts Cancer Institute at Queen Mary University of London, for example, operates a MILabs VECTor SPECT/PET/CT and a Mediso nanoScan PET/CT, each capable of imaging up to four animals at once. It also trains external users to run their own studies to help minimize costs. This shared-access model spreads scanner costs across many research groups.

The global preclinical PET/SPECT/CT systems market is moderately consolidated, with a handful of specialized instrument makers competing alongside benchtop start-ups and regional manufacturers. Bruker, MILabs, Mediso, SOFIE Biosciences, MR Solutions, and Raycan Technology compete on spatial resolution, sensitivity, quantification accuracy, isotope range, and throughput. Detector design and reconstruction software are the main differentiators. Mediso promotes its Tera-Tomo reconstruction engine, while Bruker pairs its hardware with PMOD quantification software.

Strategy is also shifting toward complete workflows. Bruker acquired Molecubes to add benchtop PET, SPECT, and CT modules, while Rigaku acquired MILabs in August 2021 to enter life science imaging. Newer entrants are targeting niches, such as MH3D with alpha-emitter SPECT. Service partnerships are becoming another route to market, as seen in the exclusive arrangement between MH3D and Perceptive Discovery.

Key Industry Developments:

• In March 2026, Bruker used the European Molecular Imaging Meeting in Ljubljana, Slovenia, to present its preclinical portfolio, including the SPECT CUBE, PET/CT systems, and PMOD software for unified quantitative analysis. The company framed its integrated approach around obtaining more endpoints from every animal.
• In February 2026, Novartis signed a long-term supply agreement with Niowave for actinium-225 to support its radioligand therapy portfolio. The deal reflects the scale of alpha-emitter investment, which is expected to generate demand for preclinical imaging capacity.
• In December 2025, a review titled Preclinical PET and SPECT Imaging in Small Animals: Technologies, Challenges and Translational Impact was published in Cells. It notes that advances in detector design, reconstruction algorithms, and multimodal integration have improved resolution, sensitivity, and quantitative accuracy.